Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b)...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2014/549709 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224839304937472 |
|---|---|
| author | Hiroshi Abe Akihito Tsubota Noritomo Shimada Masanori Atsukawa Keizo Kato Koichi Takaguchi Toru Asano Yoshimichi Chuganji Choitsu Sakamoto Hidenori Toyoda Takashi Kumada Tatsuya Ide Michio Sata Yoshio Aizawa |
| author_facet | Hiroshi Abe Akihito Tsubota Noritomo Shimada Masanori Atsukawa Keizo Kato Koichi Takaguchi Toru Asano Yoshimichi Chuganji Choitsu Sakamoto Hidenori Toyoda Takashi Kumada Tatsuya Ide Michio Sata Yoshio Aizawa |
| author_sort | Hiroshi Abe |
| collection | DOAJ |
| description | We evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients. This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin. The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis. Virological response was analyzed on an intent-to-treat basis. Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively. Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P = 7.38 × 10−4). Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10−5). However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome. |
| format | Article |
| id | doaj-art-537e87fa9ade47beb71a4ea8a2010fa2 |
| institution | OA Journals |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-537e87fa9ade47beb71a4ea8a2010fa22025-08-20T02:05:31ZengWileyGastroenterology Research and Practice1687-61211687-630X2014-01-01201410.1155/2014/549709549709Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C PatientsHiroshi Abe0Akihito Tsubota1Noritomo Shimada2Masanori Atsukawa3Keizo Kato4Koichi Takaguchi5Toru Asano6Yoshimichi Chuganji7Choitsu Sakamoto8Hidenori Toyoda9Takashi Kumada10Tatsuya Ide11Michio Sata12Yoshio Aizawa13Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, 6-41-2 Aoto, Katsushika-ku, Tokyo 125-0062, JapanInstitute of Clinical Medicine and Research, The Jikei University School of Medicine, Kashiwa, Chiba, JapanDepartment of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Chiba, JapanDivision of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Chiba, JapanDepartment of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Matsudo, Chiba, JapanDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Kagawa, JapanDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, JapanDepartment of Gastroenterology, Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, JapanDepartment of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, JapanDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu, JapanDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, JapanDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, JapanDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine Katsushika Medical Center, 6-41-2 Aoto, Katsushika-ku, Tokyo 125-0062, JapanWe evaluated the genetic variation in rs8099917, substitutions in core amino acid (aa) 70, and the number of aa substitutions in the interferon sensitivity-determining region (ISDR) on the prediction of sustained virological response (SVR) in treatment-naïve hepatitis C virus (HCV) genotype 1b (G1b) patients. This multicenter study involved 150 Asian treatment-naïve patients infected with HCV G1b who received 12 weeks of telaprevir in combination with 24 weeks of peginterferon-α-2b and ribavirin. The baseline and treatment-related factors potentially associated with SVR were determined by multivariate logistic regression analysis. Virological response was analyzed on an intent-to-treat basis. Cessation of the therapy due to adverse effects occurred in only 2 patients, who discontinued the trial at 10 weeks and at 2 weeks due to cerebral infarction and renal impairment, respectively. Among the 150 patients in whom the final virological response was determined, only genotype TT in rs8099917 was identified as a pretreatment predictor (P = 7.38 × 10−4). Achievement of a rapid virological response (RVR), defined as undetectable HCV RNA at week 4 of treatment, was identified as an after-starting-treatment predictor (P = 2.47 × 10−5). However, neither a substitution in core aa 70 nor the number of substitutions in the ISDR affected treatment outcome.http://dx.doi.org/10.1155/2014/549709 |
| spellingShingle | Hiroshi Abe Akihito Tsubota Noritomo Shimada Masanori Atsukawa Keizo Kato Koichi Takaguchi Toru Asano Yoshimichi Chuganji Choitsu Sakamoto Hidenori Toyoda Takashi Kumada Tatsuya Ide Michio Sata Yoshio Aizawa Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients Gastroenterology Research and Practice |
| title | Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients |
| title_full | Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients |
| title_fullStr | Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients |
| title_full_unstemmed | Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients |
| title_short | Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients |
| title_sort | predictors of response to 24 week telaprevir based triple therapy for treatment naive genotype 1b chronic hepatitis c patients |
| url | http://dx.doi.org/10.1155/2014/549709 |
| work_keys_str_mv | AT hiroshiabe predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT akihitotsubota predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT noritomoshimada predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT masanoriatsukawa predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT keizokato predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT koichitakaguchi predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT toruasano predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT yoshimichichuganji predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT choitsusakamoto predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT hidenoritoyoda predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT takashikumada predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT tatsuyaide predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT michiosata predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients AT yoshioaizawa predictorsofresponseto24weektelaprevirbasedtripletherapyfortreatmentnaivegenotype1bchronichepatitiscpatients |